205 related articles for article (PubMed ID: 27525431)
21. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
22. Metabolic effects of dopamine-agonists treatment among patients with prolactinomas.
Kabootari M; Shirmohammadli H; Golgiri F; Mosalamiaghili S; Khajavi A; Akbari H
Endocrine; 2023 Mar; 79(3):537-544. PubMed ID: 36352337
[TBL] [Abstract][Full Text] [Related]
23. Current treatment issues in female hyperprolactinaemia.
Crosignani PG
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):152-64. PubMed ID: 16288952
[TBL] [Abstract][Full Text] [Related]
24. Update on prolactinomas. Part 2: Treatment and management strategies.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
[TBL] [Abstract][Full Text] [Related]
25. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
26. Screening for macroprolactinaemia and pituitary imaging studies.
Hauache OM; Rocha AJ; Maia AC; Maciel RM; Vieira JG
Clin Endocrinol (Oxf); 2002 Sep; 57(3):327-31. PubMed ID: 12201824
[TBL] [Abstract][Full Text] [Related]
27. [Usefulness of cabergoline in patients with prolactinemia and resistant or intolerant to bromocriptine].
Velázquez-Chávez FJ; Tapia-González Mde L; González-Bárcena D
Cir Cir; 2009; 77(3):173-7. PubMed ID: 19671268
[TBL] [Abstract][Full Text] [Related]
28. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
[TBL] [Abstract][Full Text] [Related]
29. Hyperprolactinaemia and pituitary adenomas in adolescence.
Dissaneevate P; Warne GL
J Pediatr Endocrinol Metab; 1998; 11(4):531-41. PubMed ID: 9777574
[TBL] [Abstract][Full Text] [Related]
30. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
31. Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma.
Montalvo I; Llorens M; Caparrós L; Pamias M; Torralbas J; Giménez-Palop O; Caixàs A; Palao DJ; Labad J
Int Clin Psychopharmacol; 2018 Mar; 33(2):98-102. PubMed ID: 29035904
[TBL] [Abstract][Full Text] [Related]
32. Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapy.
Iglesias P; Macho LP; Díez JJ
Age Ageing; 2004 Jul; 33(4):410-2. PubMed ID: 15136289
[TBL] [Abstract][Full Text] [Related]
33. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
34. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
35. Prolactinoma-associated headache and dopamine agonist treatment.
Kallestrup MM; Kasch H; Østerby T; Nielsen E; Jensen TS; Jørgensen JO
Cephalalgia; 2014 Jun; 34(7):493-502. PubMed ID: 24351278
[TBL] [Abstract][Full Text] [Related]
36. Prolactinoma and pregnancy: From the wish of conception to lactation.
Maiter D
Ann Endocrinol (Paris); 2016 Jun; 77(2):128-34. PubMed ID: 27130071
[TBL] [Abstract][Full Text] [Related]
37. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.
Ciccarelli E; Grottoli S; Razzore P; Gaia D; Bertagna A; Cirillo S; Cammarota T; Camanni M; Camanni F
J Endocrinol Invest; 1997 Oct; 20(9):547-51. PubMed ID: 9413809
[TBL] [Abstract][Full Text] [Related]
38. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
Ciresi A; Amato MC; Guarnotta V; Lo Castro F; Giordano C
Clin Endocrinol (Oxf); 2013 Dec; 79(6):845-52. PubMed ID: 23506485
[TBL] [Abstract][Full Text] [Related]
39. Prolactinoma - which patients react favorably to cabergoline medication?
Karatas S; Hacioglu Y; Rakicioglu T
Endocr Regul; 2022 Oct; 56(4):279-283. PubMed ID: 36270341
[No Abstract] [Full Text] [Related]
40. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy.
Colao A; Di Sarno A; Guerra E; Pivonello R; Cappabianca P; Caranci F; Elefante A; Cavallo LM; Briganti F; Cirillo S; Lombardi G
Clin Endocrinol (Oxf); 2007 Sep; 67(3):426-33. PubMed ID: 17573902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]